Pediatric chest wall Ewing's sarcoma

Area of Science:

• Pediatric Oncology
• Thoracic Surgery
• Sarcoma Research

Background:

• Primitive neuroectodermal tumors (PNET) of the chest wall, including Ewing's sarcoma (ES), are rare malignancies with historically poor prognoses.
• Multimodality treatment approaches have improved survival rates, but the role of adjuvant radiation therapy remains uncertain.

Purpose of the Study:

• To evaluate the outcomes of patients with primitive neuroectodermal tumors (PNET) of the chest wall treated with multimodality therapy.
• To determine the impact of neoadjuvant chemotherapy and adjuvant radiation therapy on survival in patients with chest wall PNET-ES.

Main Methods:

• Retrospective analysis of 20 consecutive patients with PNET-ES of the chest wall treated between 1979 and 1998.
• Patients received varying treatment regimens including neoadjuvant chemotherapy, chest wall resection, and adjuvant chemotherapy/radiation therapy.

Main Results:

• Eleven of 20 patients (55%) achieved long-term disease-free survival (median 7.5 years).
• Neoadjuvant chemotherapy followed by resection was associated with better survival (7 of 11 survivors).
• Long-term survival was achieved in patients both with and without radiation therapy, suggesting its role may be selective.

Conclusions:

• Complete chest wall resection, potentially facilitated by neoadjuvant chemotherapy, offers a possibility for long-term survival in ES-PNET.
• Adjuvant radiation therapy is not uniformly necessary, and its use should be individualized based on patient-specific factors.
• Further research is needed to refine treatment strategies for these rare pediatric tumors.